Oncology Biosimilars Market Overview
Oncology Biosimilars Market was valued at US$ 4.5 Billion in 2024 and is projected to grow at a CAGR of 10.3% to reach US$ 10.9 Billion by 2034.
Biosimilars is a medicine which is very close in structure and function to specific biologic medicine which is also known as reference product. Biosimilars is a version of proven biologic drug. Biologic drugs are made from proteins, cells and tissues. Antibodies and vaccines are examples of biologic drugs. Biosimilar drugs are made from living organisms in different ways and with different substances. Biosimilar drugs are effective, safe and high quality treatment. Epoetin alfa-epbx (Retacrit), Pegfilgrastim-jmdb (Fulphila), Bevacizumab-awwb (Mvasi), Rituximab-pvvr (Ruxience), Trastuzumab-pkrb (Herzuma), Bevacizumab-bvzr (Zirabev), Rituximab-abbs (Truxima), Filgrastim-sndz (Zarxio), Filgrastim-aafi (Nivestym), Pegfilgrastim-cbqv (Udenyca), Trastuzumab-qyyp, Trastuzumab-dttb, are some of the U.S. FDA approved Oncology Biosimilar Drugs. Biosimilars are made from different substances so they are different from generic drugs, while generic drugs are made from same active ingredients as name of brand medication. Biosimilars manufacturing process are unique. The aim of biosimilar development program is to determine biosimilarity between the reference product and proposed biosimilar product for independently establishment of safety & effectiveness of proposed product. In January 2022, out of 33 FDA approved biosimilars 21 products are available in U.S. market. About five to nine years long period it takes in development of biosimilars. Currently around 39 biosimilar products are approved by FDA. Around $100 million to $300 million costs to develop a biosimilar products. G-CSF (granulocyte-colony stimulating factor), helps bone marrow in making more WBCs (white blood cells) to fight against infection. G-CSF (granulocyte-colony stimulating factor), is made from macrophages, endothelium and other immune cells. mAb (monoclonal antibodies) are artificial antibodies which are used in treating immune system diseases and multiple diseases of cancer. Rise in prevalence of cancer has enhanced the boost growth in Oncology Biosimilars Market.
Oncology Biosimilars Market Dynamics
Rise in prevalence of cancer diseases and rate of urbanization
Rise in prevalence of cancer disease and rate of urbanization is one of the leading factors for the Oncology Biosimilars Market growth. Urbanization has given rise in consumption of western food, processed food, frozen packed foods, alcohol, caffeine, which are unhealthy and affect the health of human being. Urbanization has given rise in disposable income which allows the individual to enhance their lifestyle, spending less on cereals, millets, fruits, vegetables, spending more on processed foods and beverages, consuming high amount of red meat and animal derived food, fats & oils, sugar, sodium, which has affected the health. Unhealthy lifestyle like Smoking, alcohol intake, low fruits and vegetable consumption, lack of exercise, low energy consumption, consumption of fat rich diet, high intake of animal derived food like red meat, rising obesity has given rise in cancer diseases. Urbanization has caused unhealthy lifestyle, change in diet, obesity, lack of exercise, pollution, late marriages fewer children, no breast feeding or lesser feeding for less duration, early menarche, late menopause, which has become major contribution in global rise of breast cancer. According to ‘The World Cancer Report 2020’ it was determined that incidence of breast cancer is consistently rising in India due to high socio-economic status and rapid urbanization. For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that breast cancers, pancreas, prostate, colorectal and lung cancers increasing with rate of urbanization. 90th percentile was maximum increase rate of breast cancer. 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, 95th percentile for lung cancer and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. For instance, in 2020, according to (PMC), urban population was 36.6% to 44.8% in 1970-1994 and expected to increase till 61.1% till 2025. Around 70%-80% of colorectal cancer incidence in urban population occurs due to unhealthy lifestyle and environmental factors. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. Use of biosimilars in oncology is used in treating various types of cancer and also the side-effects of cancer treatment. However, the growth in prevalence of cancer diseases and population in urban areas boosts the demand for Oncology Biosimilars market.
Restrains:
However, difficulty in process of making biosimilars, difference in protein folding which are hard to predict and immunogenicity, lack of awareness and education among people about biosimilar may somewhat restrain the oncology biosimilars market growth.
Oncology Biosimilars Market Segmentation
Oncology Biosimilars Market is segmented based on cancer type, drug class, distribution channel and region.
Cancer Type Insight
On the basis of Cancer Type Oncology Biosimilars Market is segmented into Lung Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, and Others. Breast cancer has dominated the target market growth because incidence of breast cancer are rising due to unhealthy lifestyle, poor nutrition food, obesity, use of alcohol, and aging population.
Drug Class Insights
On the basis of Drug Class Oncology Biosimilars Market is segmented into Hematopoietic Agents, G-CSF (granulocyte-colony stimulating factor), mAb (monoclonal antibodies) and others. mAb (monoclonal antibodies) has dominated the target market growth because of its effectiveness in medical treatment and large scale production of identical antibody molecules.
Distribution Channel
On the basis of Distribution Channel Oncology Biosimilars Market is segmented into Hospitals, Online Pharmacy, Retail Pharmacy, and Others. Hospitals has dominated the target market due to its advanced facilities, and individual care.
Regional Insights:
On region the Oncology Biosimilars Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising prevalence of cancer disease, presence of top key players, and rise in number of approved biosimilar products is anticipated to increase demand for Oncology Biosimilars in the region.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2023 |
|
Forecast period |
2024 – 2034 |
|
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
|
Market Segmentation |
By Cancer Type - Lung Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, and others By Drug Class - Hematopoietic Agents, G-CSF (granulocyte-colony stimulating factor), mAb (monoclonal antibodies) and others By Distribution Channel - Hospitals, Online Pharmacy, Retail Pharmacy, and others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Oncology Biosimilars Market report based on cancer type, drug class, distribution channel and region:
Oncology Biosimilars Market, By Cancer Type:
- Lung Cancer
- Blood Cancer
- Breast Cancer
- Cervical Cancer
- Others
Oncology Biosimilars Market, By Drug Class:
- Hematopoietic Agents
- G-CSF (granulocyte-colony stimulating factor)
- mAb (monoclonal antibodies)
- Others
Oncology Biosimilars Market, By Distribution Channel:
- Hospitals
- Online Pharmacy
- Retail Pharmacy
- Others
Oncology Biosimilars Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Oncology Biosimilars Market Key Players
The key players operating the Oncology Biosimilars Market includes,
- Amgen Inc.,
Amgen Inc., is the leading biotechnology company in the world. Amgen is a discoverer, developer, manufacturer, and delivers innovative human therapeutic products in oncology, cardiovascular disease, nephrology & inflammation, bone health, etc. Amgen produce high quality biosimilars in oncology.
- Biocon Limited.
Biocon Limited., is a global biopharmaceutical company. Biocon offers treatment in cancer, diabetes, and autoimmune diseases. Biocon offers drug discover, drug delivery, and high-quality healthcare products which are affordable for patients. Biocon provides biosimilars, generics, novel biologics and research services.
- Pfizer Inc.
Pfizer is the manufacturer of drug products, active pharmaceutical ingredients (API), and medical devices in various diseases. Pfizer offers internal medicine, vaccines, treatment in oncology, inflammation & immunology and others.
- Teva Pharmaceuticals Industries Ltd.
Teva Pharmaceuticals is an Israeli multinational pharmaceutical company which headquartered in Tel Aviv Israel. Teva Pharmaceuticals is the global leader in biopharmaceuticals, biosimilars and generic products.
- Novartis International AG.
Novartis International AG., is a Swiss-American multinational pharmaceutical company. Novartis International AG., is the world’s largest healthcare company which is a global leader in generic and biosimilar medicines.
- Amneal
Amneal, offers medications in treating cancer, women’s health issues, cardiovascular, diabetes, urologic, central nervous system disease, opioid dependency, dermatologic conditions and others. Amneal, offers generic and biosimilar medicines.
- Synthon Pharmaceuticals Inc.
Synthon Pharmaceuticals is science-centered and international pharmaceutical company. Synthon is a developer and manufacturer of high-quality hybrid and generic medicines for patients around the world.
- Boehringer Ingelhiem,
Boehringer Ingelhiem, is a global pharmaceutical company in Germany which develops therapies in oncology, metabolic diseases, cardiovascular diseases, respiratory, immunology diseases, etc. Boehringer Ingelhiem, also produce biosimilar products.
- Gedeon Richter
Gedeon Richter is headquartered in Hungary. Gedeon Richter is developing therapies in various sector like cardiovascular, central nervous system and women’s healthcare. Gedeon Richter also produce biosimilar products.
- Fresenius Kabi
Fresenius Kabi, is headquartered in Germany. Fresenius Kabi is a global healthcare company with portfolio of infusion therapies, IV generic drugs, biosimilars in oncology & autoimmune diseases, and clinical nutrition products.
Recent Development:
- In October 2022, Amneal has launched First Biosimilar ‘ALYMSYS (bevacizumab-maly)’ in U.S. which is biosimilar referencing Avastin. ‘ALYMSYS’ will be used in oncology as a vascular endothelial growth factor inhibitor. Newly launched biosimilar will be used in treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, primary peritoneal cancer, metastatic cervical cancer and metastatic renal cell carcinoma. ‘ALYMSYS’ will help in providing additional access & choices to affordable and cost-effective oncology therapeutics for patients & providers.
Oncology Biosimilars Market Company Profile
- Amneal*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Amgen Inc.
- Biocon Limited.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis International AG
- Synthon Pharmaceuticals Inc.
- Boehringer Ingelhiem
- Gedeon Richter
- Fresenius Kabi
“*” marked represents similar segmentation in other categories in the respective section
Oncology Biosimilars Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Cancer Type
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restrains
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market segmentation, By Cancer Type
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Lung Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Blood Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Breast Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Cervical Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market segmentation, By Drug Class, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Hematopoietic Agents
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- G-CSF (granulocyte-colony stimulating factor)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- mAb (monoclonal antibodies)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market segmentation, By Distribution Channel, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Online Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Retail Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Global Market, By Region, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Cancer Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Drug Class, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Cancer Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Drug Class, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Cancer Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Drug Class, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Cancer Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Drug Class, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Cancer Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Drug Class, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Amgen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Biocon Limited.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Novartis International AG.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Amneal
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Synthon Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Boehringer Ingelhiem
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Gedeon Richter
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Fresenius Kabi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Oncology Biosimilars Market is segmented into cancer type, drug class, distribution channel, and region.
Oncology Biosimilars Market is driven by factors like rise in prevalence of cancer diseases, and rate of urbanization.
By region, the Oncology Biosimilars market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.
The key players operating the Oncology Biosimilars Market includes, Amgen Inc., Biocon Limited, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis International AG., Amneal, Synthon Pharmaceuticals Inc., Boehringer Ingelhiem, Gedeon Richter, Fresenius Kabi, and others.